February 20, 2012 — BG Medicine, Inc. announced positive results from its pivotal validation study for the CardioSCORE diagnostic test, previously known by the development name AMIPredict.

February 20, 2012 — Biopharmaceutical company Celladon Corp. this week completed a $43 million equity financing to advance its lead investigational drug candidate Mydicar for the treatment of heart failure.

February 20, 2012 — As part of president Obama’s pledge to reduce regulatory burden, Health and Human Services (HHS) secretary Kathleen Sebelius announced HHS will postpone the date at which certain health care entities have to comply with International Classification of Diseases, 10th Edition (ICD-10) diagnosis and procedure codes.


As catheter-based, minimally invasive procedures expand rapidly beyond treatment of the coronary arteries into all areas of the human anatomy, angiography X-ray imaging systems have moved beyond their original purpose of simple vascular imaging. Today, in addition to interventional cardiology, cath labs are frequently shared by numerous specialists, including interventional radiology, interventional oncology, electrophysiology (EP), vascular surgeons and neurology.

February 16, 2012 — U.S. Food and Drug Administration (FDA) granted 510(k) clearance for AngioDynamics NeverTouch Direct procedure kit for use with the company’s VenaCure EVLT laser vein ablation system. The NeverTouch Direct kit offers physicians the ability to treat varicose veins with fewer procedure steps by eliminating the need for a long guidewire or guiding sheath, while continuing to deliver to patients less pain and bruising compared to bare-tip fibers.

February 16, 2012 — A partnership between the American Society of Echocardiography (ASE) and GE Healthcare used technological innovations in the field to bring cardiovascular ultrasound to an underserved population in rural India.

February 16, 2012 — Few hospitals have as much experience with the Berlin Heart pediatric ventricular assist device (VAD) as DMC Children's Hospital of Michigan. This is why the U.S. Food and Drug Administration (FDA) was eager to hear testimony from Henry L. Walters III, M.D., the hospital’s chief of cardiovascular surgery.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now